06/12/2018 18:01:00

Honolulu Ophthalmologist Implants First Visian® Toric ICL in Hawaii

HONOLULU, Dec. 06, 2018 (GLOBE NEWSWIRE) -- On December 17, 2018 Honolulu ophthalmologist and experienced eye surgeon Alan Faulkner, MD, performed the first surgical implantation of the Visian Toric ICL (TICL) on the Hawaiian islands. Dr. Faulkner explains this important milestone marks a significant advancement in the field of vision correction, and broadens the scope of candidates at Aloha Laser Vision that can be helped with ICL technology. Surgery to implant the standard Visian ICL—approved by the FDA in 2005—is only a suitable option for patients with myopia; however, the innovation of the TICL now allows for the correction of astigmatism as well.

The Visian Toric ICL is an Implantable Collamer® Lens (ICL) designed specifically to correct for myopic astigmatism (nearsightedness and astigmatism), which is caused by imperfections in the curvature of the lens or an irregularly shaped cornea. On September 13, 2018 the Visian TICL received FDA-approval, and Dr. Faulkner is among the first wave of ophthalmologists in the United States who have moved forward with implanting the TICL in patients. In STAAR’s clinical trials, TICL implantation produced excellent long-term treatment results—“with 94.6% of patients reporting excellent or very good vision quality.”

Dr. Faulkner says that patients with myopia and astigmatism who are not good candidates for laser vision correction procedures (i.e. LASIK and PRK)—often those with thin corneas or dry eyes—can consider implantation of the TICL to achieve better sight and reduce reliance on contacts and glasses. The TICL is implanted during a 20 to 30 minute procedure as a secondary lens, which is able to provide the specific degree of vision correction the patient needs. This means the cornea does not have to be reshaped or replaced, and the procedure is completely reversible. The new TICL also saves time for vision correction patients with myopic astigmatism who frequently require multiple procedures (with other methods) to achieve excellent vision.

As advancements in vision correction like the TICL continue to emerge, Dr. Faulkner and his team remain committed to adopting these new techniques and technologies to provide their patients with state-of-the-art care.

About Alan Faulkner, MD

Dr. Faulkner

is board-certified by the American Board of Ophthalmology, and the lead eye surgeon at Aloha Laser Vision. Since 2001 he has expanded his practice into a state-of-the-art laser vision correction center offering a broad spectrum of premium services, including LASIK, cataract surgery, and aesthetic treatments. Dr. Faulkner received his medical degree from Tulane Medical School and went on to complete an internship in Internal Medicine, a residency in Ophthalmology, and a fellowship in Oculoplastics, Ocular Oncology, and Orbital Disease. Prior to establishing Aloha Laser Vision, Dr. Faulkner was a full-time Assistant Professor of Ophthalmology at Tulane. He maintains active membership in several professional organizations, including the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgeons, and the International Society of Refractive Surgeons. He is available for interview upon request.

For more information about Dr. Faulkner and his practice, please visit alohalaservision.com and facebook.com/alohalaservision.

To view the original source of this press release, click here:  https://www.alohalaservision.com/news-room/honolulu-ophthalmologist-implants-first-visian-toric-icl-in-hawaii/

Aloha Laser Vision

1100 Ward Ave., Ste. 1000

Honolulu, Hawaii 96814

(808) 972-3937

Rosemont Media

(858) 200-0044

www.rosemontmedia.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2cb65042-c364-4676-9022-4d47c01428d6

Aloha947392.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
61
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
19 Feb
FING-B
Så lukkede FPC over den gamle modstand i dag i 19,55 modstanden var 19,47 og næste stop er nu 21,786..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
18 Feb
VWS
VESTAS LEADS BREAK-AWAY GROUP OF ONSHORE TURBINE MAKERS (fra 16% til 22% af det totale marked for la..
17
18 Feb
PNDORA
Det er netop kommet frem, at tyske BAFIN, svarende til Finanstilsynet i Dk., har forbudt short posit..
17
19 Feb
VELO
Til dem af jer der ikke er med i FB gruppen: Canada havde, sammen med US, lukket i går. Teorien er, ..
15
18 Feb
CHEMM
Puha, ja hvad venter vi nu på,…… vi trofaste og frelste Chemo aktionærer, Noten, den romantiske og ..
15
18 Feb
VELO
Sjovt at se dem der hårdnakket har påstået, at de er langt også er dem der sælger. Samme personer de..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
2
ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338 million
3
Hillcrest Labs and LG Renew License for Smart TV Technology
4
Exantas Capital Corp. to Report Operating Results for Fourth Quarter 2018
5
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Health Insurance Innovations, Inc. (HIIQ) and Encourages HIIQ Investors to Contact the Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 February 2019 22:46:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB7 - 2019-02-20 23:46:22 - 2019-02-20 22:46:22 - 1000 - Website: OKAY